A Prospective, Randomized Comparison of Promus Everolimus-Eluting and TAXUS Liberte Paclitaxel-Eluting Stent Systems in Patients with Coronary Artery Disease Eligible for Percutaneous Coronary Intervention: The PROMISE Study

作者：Kim Ung; Lee Chan Hee; Jo Jung Hwan; Lee Hyun Wook; Choi Yoon Jung; Son Jang Won; Lee Sang Hee; Park Jong Seon; Shin Dong Gu; Kim Young Jo^*; Jeong Myung Ho; Cho Myung Chan; Bae Jang Ho; Lee Jae Hwan; Kang Tae Soo; Jung Kyung Tae; Jung Kyung Ho; Lee Seung Wook; Cho Jang Hyun; Kim Won; Hur Seung Ho; Kim Ki Sik; Park Heon Sik; Kim Moo Hyun; Hwang Jin Yong; Kim Doo Il; Kim Tae Ik

来源：Journal of Korean Medical Science, 2013, 28(11): 1609-1614.

DOI：10.3346/jkms.2013.28.11.1609

• Everolimus-Eluting Stent
• Paclitaxel-Eluting Stent

We aimed comparing two-year clinical outcomes of the Everolimus-Eluting Promus and Paclitaxel-Eluting TAXUS Liberte stents used in routine clinical practice. Patients with objective evidence of ischemia and coronary artery disease eligible for PCI were prospectively randomized to everolimus-eluting stent (EES) or paclitaxel-eluting stent (PES) groups. The primary end-point was ischemia-driven target vessel revascularization (TVR) at 2 yr after intervention, and the secondary end-point was a major adverse cardiac event (MACE), such as death, myocardial infarction (MI), target lesion revascularization (TLR), TVR or stent thrombosis. A total of 850 patients with 1,039 lesions was randomized to the EES (n = 425) and PES (n = 425) groups. Ischemic-driven TVR at 2 yr was 3.8% in the PES and 1.2% in the EES group (P for non-inferiority = 0.021). MACE rates were significantly different; 5.6% in PES and 2.5% in EES (P = 0.027). Rates of MI (0.8% in PES vs 0.2% in EES, P = 0.308), all deaths (1.5% in PES vs 1.2% in EES, P = 0.739) and stent thrombosis (0.3% in PES vs 0.7% in EES, P = 0.325) were similar. The clinical outcomes of EES are superior to PES, mainly due to a reduction in the rate of ischemia-driven TVR.

• 出版日期2013-11